We are live on ! Find out more
BG

Bahl & Gaynor Portfolio holdings

AUM $19.8B
1-Year Est. Return 19.53%
This Fund
S&P 500
This Quarter Est. Return
-0.12%
1 Year Est. Return
+19.53%
3 Year Est. Return
+63.97%
5 Year Est. Return
+84.2%
10 Year Est. Return
+296.44%
AUM
$6.71B
AUM Growth
+$133M
Cap. Flow
+$178M
Cap. Flow %
2.66%
Top 10 Hldgs %
26.7%
Holding
442
New
38
Increased
200
Reduced
128
Closed
18

Top Buys

Rank Stock Value
1
MMM icon
3M
MMM
+$44.9M
2
HSY icon
Hershey
HSY
+$33.9M
3
VTR icon
Ventas
VTR
+$33.1M
4
PAYX icon
Paychex
PAYX
+$31M
5
PEP icon
PepsiCo
PEP
+$26.1M

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$54.8M
2
AAPL icon
Apple
AAPL
+$24M
3
O icon
Realty Income
O
+$21.6M
4
CFR icon
Cullen/Frost Bankers
CFR
+$17.6M
5
IBM icon
IBM
IBM
+$8.55M

Sector Composition

Rank Sector Weight
1 Healthcare 16.26%
2 Consumer Staples 15.49%
3 Technology 15.18%
4 Industrials 11.77%
5 Energy 10.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
WAB icon
251
Wabtec
WAB
$49.8B
$654K 0.01%
8,070
+115
+1% +$9.49K
RBA icon
252
RB Global
RBA
$17.3B
$649K 0.01%
28,999
+10,961
+61% +$261K
ROL icon
253
Rollins
ROL
$17.6B
$638K 0.01%
73,497
+8,960
+14% +$78.4K
JJSF icon
254
J&J Snack Foods
JJSF
$1.72B
$632K 0.01%
6,755
+380
+6% +$35.8K
MOV icon
255
Movado Group
MOV
$842M
$626K 0.01%
18,945
+10,210
+117% +$400K
TIS
256
DELISTED
Orchids Paper Products, Inc.
TIS
$624K 0.01%
25,410
+7,695
+43% +$214K
UNFI icon
257
United Natural Foods
UNFI
$2.92B
$615K 0.01%
10,006
+1,258
+14% +$79K
VIVO
258
DELISTED
Meridian Bioscience Inc
VIVO
$610K 0.01%
34,490
-10,678
-24% -$210K
NVO
259
Novo Nordisk
NVO
$203B
$599K 0.01%
25,160
-1,600
-6% -$36.8K
EAT icon
260
Brinker International
EAT
$9.8B
$598K 0.01%
11,773
+1,420
+14% +$68.1K
IJR icon
261
iShares Core S&P Small-Cap ETF
IJR
$112B
$597K 0.01%
11,444
+170
+2% +$9.25K
RSG icon
262
Republic Services
RSG
$64.2B
$581K 0.01%
14,875
+6,910
+87% +$266K
NATI
263
DELISTED
National Instruments Corp
NATI
$576K 0.01%
18,622
+1,995
+12% +$64.6K
HBAN icon
264
Huntington Bancshares
HBAN
$35.2B
$574K 0.01%
59,003
+200
+0.3% +$1.96K
BLKB icon
265
Blackbaud
BLKB
$2.06B
$570K 0.01%
14,503
+1,770
+14% +$65.9K
ETP
266
DELISTED
Energy Transfer Partners, L.P.
ETP
$560K 0.01%
11,600
IPAR icon
267
Interparfums
IPAR
$3.87B
$559K 0.01%
20,316
+1,475
+8% +$41.7K
IBKC
268
DELISTED
IBERIABANK Corp
IBKC
$558K 0.01%
8,928
+365
+4% +$24.1K
MWIV
269
DELISTED
MWI VETERINARY SUPPLY, INC.
MWIV
$555K 0.01%
3,742
+655
+21% +$94.2K
SHW icon
270
Sherwin-Williams
SHW
$88.2B
$547K 0.01%
+7,500
New +$532K
TXN icon
271
Texas Instruments
TXN
$257B
$546K 0.01%
11,445
+1,100
+11% +$52.7K
MENT
272
DELISTED
Mentor Graphics Corp
MENT
$544K 0.01%
26,502
+11,500
+77% +$246K
ESV
273
DELISTED
Ensco Rowan plc
ESV
$529K 0.01%
3,200
+293
+10% +$58.1K
ROST icon
274
Ross Stores
ROST
$81.2B
$519K 0.01%
13,738
-440
-3% -$15.3K
TRIB
275
Trinity Biotech
TRIB
$7.88M
$519K 0.01%
189
+26
+16% +$84.5K

Similar funds

Bahl & Gaynor's Q3 2014 Portfolio in Review

As of Q3 2014, Bahl & Gaynor held 442 positions worth $6.71B, up 2% from $6.58B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Bahl & Gaynor's Q3 2014 filing shows 38 new, 200 increased, 128 reduced and 18 closed positions. Its largest new stake was Cracker Barrel: 9,775 shares worth $1.01M. The largest sale was GSK, an estimated $54.8M.

By sector, the portfolio is most concentrated in Healthcare at 16% of assets, down from 17% a quarter earlier, followed by Consumer Staples and Technology.

  • Bahl & Gaynor's largest Q3 2014 buy was Cracker Barrel: 9,775 shares worth $1.01M.
  • Bahl & Gaynor added most to 3M in Q3 2014, an estimated $44.9M increase.
  • Bahl & Gaynor's biggest Q3 2014 reduction was GSK, cutting an estimated $54.8M.
  • Bahl & Gaynor fully exited GNC Holdings, Inc. in Q3 2014, selling an estimated $2.07M.
  • Bahl & Gaynor's ten largest holdings make up 27% of its $6.71B portfolio in Q3 2014.
  • Bahl & Gaynor opened 38 new positions and closed 18 in Q3 2014.
  • Bahl & Gaynor's portfolio value rose 2% quarter-over-quarter to $6.71B.

Based on Bahl & Gaynor's 13F filing for Q3 2014, filed 12 Nov 2014.